[Action mechanisms of anti-obesity drugs]. 2009

Daiji Nagayama, and Kohji Shirai
Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center.

Principle of the treatment of obesity is diet and exercise therapy. However, it is extremely difficult to maintain the effect in the long term. In recent years, mechanism of appetite center and adaptive thermogenesis is gradually clarified. As a tool of new treatment of obesity, anti-obesity drugs come to attract attention in this way. However, anti-obesity drug is not the all-around procedure that has got thinner easily if we use it. Anti-obesity drug should be used carefully to show the availability after having understood each action mechanism. Other than mazindol approved alone in Japan, we explain it in this chapter about sibutramine and rimonabant those are on the clinical trial now. We will mention an adaptation of a certain anti-obesity drug in the middle of an argument.

UI MeSH Term Description Entries
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D019440 Anti-Obesity Agents Agents that increase energy expenditure and weight loss by neural and metabolic regulation. Anti-Obesity Agent,Anti-Obesity Drug,Antiobesity Agent,Antiobesity Drug,Weight-Loss Agents,Weight-Loss Drug,Anti-Obesity Drugs,Antiobesity Agents,Antiobesity Drugs,Weight-Loss Drugs,Agent, Anti-Obesity,Agent, Antiobesity,Agents, Anti-Obesity,Agents, Antiobesity,Agents, Weight-Loss,Anti Obesity Agent,Anti Obesity Agents,Anti Obesity Drug,Anti Obesity Drugs,Drug, Anti-Obesity,Drug, Antiobesity,Drug, Weight-Loss,Drugs, Anti-Obesity,Drugs, Antiobesity,Drugs, Weight-Loss,Weight Loss Agents,Weight Loss Drug,Weight Loss Drugs

Related Publications

Daiji Nagayama, and Kohji Shirai
November 2014, Molecules (Basel, Switzerland),
Daiji Nagayama, and Kohji Shirai
January 1976, General pharmacology,
Daiji Nagayama, and Kohji Shirai
February 1999, Biochemical Society transactions,
Daiji Nagayama, and Kohji Shirai
June 2022, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Daiji Nagayama, and Kohji Shirai
July 2005, Mini reviews in medicinal chemistry,
Daiji Nagayama, and Kohji Shirai
January 1987, Archives des maladies du coeur et des vaisseaux,
Daiji Nagayama, and Kohji Shirai
April 2014, Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology,
Daiji Nagayama, and Kohji Shirai
February 2013, Trends in neurosciences,
Daiji Nagayama, and Kohji Shirai
June 2001, International journal of clinical pharmacology and therapeutics,
Daiji Nagayama, and Kohji Shirai
January 2008, Current medicinal chemistry,
Copied contents to your clipboard!